PA
AGIO icon

Perceptive Advisors’s Agios Pharmaceuticals AGIO Stock Holding History

Perceptive Advisors’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-100,000
Closed -$2.92M – 112
2024
Q1 		$2.92M Buy
+100,000
New +$2.68M 0.05% 102
2019
Q2 		– Sell
-200,000
Closed -$140K – 107
2019
Q1 		$140K Buy
+200,000
New +$11.6M ﹤0.01% 99

Other funds holding AGIO

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Perceptive Advisors's AGIO Position: Q3 2020 in Review

Perceptive Advisors sold out of Agios Pharmaceuticals (AGIO) in Q3 2020, closing a stake of 900,000 shares — an estimated $48.1M sold.

Perceptive Advisors first reported a position in AGIO in Q1 2018 and held it in 4 quarters. The position peaked at $48.1M in Q2 2020. 214 funds tracked by Wall St. Rank hold AGIO as of Q3 2020.

  • Perceptive Advisors reported no remaining Agios Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Perceptive Advisors sold 900,000 Agios Pharmaceuticals shares in Q3 2020, an estimated $48.1M.
  • Perceptive Advisors first reported a position in Agios Pharmaceuticals in Q1 2018 and held it in 4 quarters.
  • Perceptive Advisors's Agios Pharmaceuticals position peaked at $48.1M in Q2 2020.
  • 214 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q3 2020.

Based on Perceptive Advisors's 13F filing for Q3 2020, filed 16 Nov 2020.